유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
dimethyl fumarate teva
teva gmbh - dimetüülfumaraat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
dimethyl fumarate accord
accord healthcare s.l.u. - dimetüülfumaraat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosupressandid - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
tecfidera
biogen netherlands b.v. - dimetüülfumaraat - hulgiskleroos - immunosupressandid - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
synjardy
boehringer ingelheim - empagliflozin, metformiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - synjardy on näidustatud täiskasvanutel vanuses 18 aastat ja vanemad, tüüp 2 diabeet lisandina toitumise ja treeningu parandamiseks glycaemic hõlma järgmist:patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin üksi;patsientidel, ebapiisavalt kontrollitud metformiin koos teiste glükoosi-langetavaid ravimeid, kaasa arvatud insuliin;patsientidel, juba ravitakse kombinatsioon empagliflozin ja metformiin kui eraldi tabletid.
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neuromuskulaarne blokaad - kõik muud ravitoimingud - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulaarne blokaad - kõik muud ravitoimingud - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskulaarne blokaad - kõik muud ravitoimingud - rookurooniumi või vekurooniumi poolt indutseeritud neuromuskulaarse blokaadi pöördumine. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neuromuskulaarne blokaad - sugammadeks - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulaarne blokaad - kõik muud ravitoimingud - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
유럽 연합 -
에스토니아어 -
EMA (European Medicines Agency)
ritonavir mylan
mylan s.a.s - ritonaviir - hiv-nakkused - viirusevastased ravimid süsteemseks kasutamiseks - ritonaviiriga on näidustatud kombinatsioonis teiste retroviirusevastaste ravimitega hiv-1 infektsiooniga patsientidel (täiskasvanutel ja lastel 2 aastat ja vanemad).